Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Dose uniformity of budesonide Easyhaler® under simulated real-life conditions and with low inspiration flow rates.

Haikarainen J, Rytilä P, Roos S, Metsärinne S, Happonen A.

Chron Respir Dis. 2018 Aug;15(3):265-271. doi: 10.1177/1479972317745733. Epub 2017 Dec 7.

2.

Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.

Hantulik P, Wittig K, Henschel Y, Ochse J, Vahteristo M, Rytila P.

Pneumonol Alergol Pol. 2015;83(5):365-77. doi: 10.5603/PiAP.2015.0059.

3.

Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Malmberg LP, Rytilä P, Happonen P, Haahtela T.

Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:257-62.

4.

Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study.

Louhelainen N, Stark H, Mazur W, Rytilä P, Djukanovic R, Kinnula VL.

BMC Pulm Med. 2010 Mar 14;10:13. doi: 10.1186/1471-2466-10-13.

5.

Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma.

Haahtela T, Tamminen K, Kava T, Malmberg LP, Rytilä P, Nikander K, Persson T, Selroos O.

J Allergy Clin Immunol. 2009 Dec;124(6):1180-5. doi: 10.1016/j.jaci.2009.09.036.

PMID:
20004779
6.

Linkage between smoking and asthma.

Pietinalho A, Pelkonen A, Rytilä P.

Allergy. 2009 Dec;64(12):1722-7. doi: 10.1111/j.1398-9995.2009.02208.x. Epub 2009 Oct 12. Review.

PMID:
19832738
7.

Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children.

Obase Y, Rytilä P, Metso T, Pelkonen AS, Tervahartiala T, Turpeinen M, Mäkelä M, Saarialho-Kere U, Selroos O, Sorsa T, Haahtela T.

Int Arch Allergy Immunol. 2010;151(3):247-54. doi: 10.1159/000242362. Epub 2009 Sep 29.

PMID:
19786805
8.

Persistence of oxidant and protease burden in the airways after smoking cessation.

Louhelainen N, Rytilä P, Haahtela T, Kinnula VL, Djukanović R.

BMC Pulm Med. 2009 May 27;9:25. doi: 10.1186/1471-2466-9-25.

9.

The use of microspirometry in detecting lowered FEV1 values in current or former cigarette smokers.

Rytila P, Helin T, Kinnula V.

Prim Care Respir J. 2008 Dec;17(4):232-7. doi: 10.3132/pcrj.2008.00058.

10.

Physical training does not increase allergic inflammation in asthmatic children.

Moreira A, Delgado L, Haahtela T, Fonseca J, Moreira P, Lopes C, Mota J, Santos P, Rytilä P, Castel-Branco MG.

Eur Respir J. 2008 Dec;32(6):1570-5. doi: 10.1183/09031936.00171707. Epub 2008 Aug 6.

11.

Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function.

Rytilä P, Ghaly L, Varghese S, Chung W, Selroos O, Haahtela T; Airway Inflammation Study Group.

Eur Respir J. 2008 Oct;32(4):989-96. doi: 10.1183/09031936.00062307. Epub 2008 May 28.

12.

Competitive swimmers with allergic asthma show a mixed type of airway inflammation.

Moreira A, Delgado L, Palmares C, Lopes C, Jacinto T, Rytilä P, Silva JA, Castel-Branco MG, Haahtela T.

Eur Respir J. 2008 May;31(5):1139-41. doi: 10.1183/09031936.00175207. No abstract available.

13.

Elevated expression and activation of matrix metalloproteinase 8 in tear fluid in atopic blepharoconjunctivitis.

Määttä M, Kari O, Tervahartiala T, Wahlgren J, Peltonen S, Kari M, Rytilä P, Saari M, Sorsa T.

Cornea. 2008 Apr;27(3):297-301. doi: 10.1097/ICO.0b013e31815c18d6.

PMID:
18362656
14.

The value of sputum 8-isoprostane in detecting oxidative stress in mild asthma.

Louhelainen N, Rytilä P, Obase Y, Mäkelä M, Haahtela T, Kinnula VL, Pelkonen A.

J Asthma. 2008 Mar;45(2):149-54. doi: 10.1080/02770900701840261.

PMID:
18350407
15.

Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.

Ilumets H, Rytilä P, Demedts I, Brusselle GG, Sovijärvi A, Myllärniemi M, Sorsa T, Kinnula VL.

Int J Chron Obstruct Pulmon Dis. 2007;2(3):369-79.

16.

Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation.

Ilumets H, Rytilä PH, Sovijärvi AR, Tervahartiala T, Myllärniemi M, Sorsa TA, Kinnula VL.

Scand J Clin Lab Invest. 2008;68(7):618-23. doi: 10.1080/00365510801983773.

PMID:
19378434
17.

Enhancement of neutrophil function by the bronchial epithelium stimulated by epidermal growth factor.

Uddin M, Seumois G, Lau LC, Rytila P, Davies DE, Djukanovic R.

Eur Respir J. 2008 Apr;31(4):714-24. Epub 2007 Dec 19.

18.

Apoptotic mechanisms in the pathogenesis of COPD.

Plataki M, Tzortzaki E, Rytila P, Demosthenes M, Koutsopoulos A, Siafakas NM.

Int J Chron Obstruct Pulmon Dis. 2006;1(2):161-71. Review.

19.

Topical tacrolimus in the treatment of atopic dermatitis--does it benefit the airways? A 4-year open follow-up.

Virtanen H, Remitz A, Malmberg P, Rytilä P, Metso T, Haahtela T, Reitamo S.

J Allergy Clin Immunol. 2007 Dec;120(6):1464-6. Epub 2007 Oct 1. No abstract available.

PMID:
17910892
20.

Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases.

Vuorinen K, Myllärniemi M, Lammi L, Piirilä P, Rytilä P, Salmenkivi K, Kinnula VL.

APMIS. 2007 Aug;115(8):969-75.

PMID:
17696954
21.

Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients.

Harju TH, Peltoniemi MJ, Rytilä PH, Soini Y, Salmenkivi KM, Board PG, Ruddock LW, Kinnula VL.

Respir Res. 2007 Jul 6;8:48.

22.

Thiol proteins, redox modulation and parenchymal lung disease.

Kinnula VL, Vuorinen K, Ilumets H, Rytilä P, Myllärniemi M.

Curr Med Chem. 2007;14(2):213-22. Review.

PMID:
17266580
23.

Voisiko keuhkoahtaumataudin seulonnalla olla vaikutusta?

Kinnula V, Myllärniemi M, Rytilä P.

Duodecim. 2006;122(21):2555-6. Finnish. No abstract available.

PMID:
17233331
24.

Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease.

Peltoniemi MJ, Rytilä PH, Harju TH, Soini YM, Salmenkivi KM, Ruddock LW, Kinnula VL.

Respir Res. 2006 Oct 25;7:133.

25.

8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD.

Kinnula VL, Ilumets H, Myllärniemi M, Sovijärvi A, Rytilä P.

Eur Respir J. 2007 Jan;29(1):51-5. Epub 2006 Oct 18.

26.

Airway neutrophilia in COPD is not associated with increased neutrophil survival.

Rytilä P, Plataki M, Bucchieri F, Uddin M, Nong G, Kinnula VL, Djukanovic R.

Eur Respir J. 2006 Dec;28(6):1163-9. Epub 2006 Sep 13.

27.

Downstream target genes of the neuropeptide S-NPSR1 pathway.

Vendelin J, Bruce S, Holopainen P, Pulkkinen V, Rytilä P, Pirskanen A, Rehn M, Laitinen T, Laitinen LA, Haahtela T, Saarialho-Kere U, Laitinen A, Kere J.

Hum Mol Genet. 2006 Oct 1;15(19):2923-35. Epub 2006 Aug 22.

PMID:
16926187
28.

Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD.

Rytilä P, Rehn T, Ilumets H, Rouhos A, Sovijärvi A, Myllärniemi M, Kinnula VL.

Respir Res. 2006 Apr 28;7:69.

29.

Neuropeptide S and G protein-coupled receptor 154 modulate macrophage immune responses.

Pulkkinen V, Majuri ML, Wang G, Holopainen P, Obase Y, Vendelin J, Wolff H, Rytilä P, Laitinen LA, Haahtela T, Laitinen T, Alenius H, Kere J, Rehn M.

Hum Mol Genet. 2006 May 15;15(10):1667-79. Epub 2006 Apr 6.

PMID:
16600990
30.

Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma.

Harju TH, Leinonen M, Nokso-Koivisto J, Korhonen T, Räty R, He Q, Hovi T, Mertsola J, Bloigu A, Rytilä P, Saikku P.

Thorax. 2006 Jul;61(7):579-84. Epub 2006 Mar 3.

31.

[Early diagnosis of obstructive pulmonary disease from functional tests to inflammation detection].

Rytilä P, Kinnula V.

Duodecim. 2005;121(22):2421-30. Review. Finnish. No abstract available.

PMID:
16457073
32.

Respiratory symptoms, bronchial hyper-responsiveness, and eosinophilic airway inflammation in patients with moderate-to-severe atopic dermatitis.

Kyllönen H, Malmberg P, Remitz A, Rytilä P, Metso T, Helenius I, Haahtela T, Reitamo S.

Clin Exp Allergy. 2006 Feb;36(2):192-7.

PMID:
16433856
33.

Determinants of increased exhaled nitric oxide in patients with suspected asthma.

Malmberg LP, Turpeinen H, Rytilä P, Sarna S, Haahtela T.

Allergy. 2005 Apr;60(4):464-8.

PMID:
15727577
34.

Induced sputum in children with newly diagnosed mild asthma: the effect of 6 months of treatment with budesonide or disodium cromoglycate.

Rytilä P, Pelkonen AS, Metso T, Nikander K, Haahtela T, Turpeinen M.

Allergy. 2004 Aug;59(8):839-44.

35.

Chlamydia pneumoniae infection and inflammation in adults with asthma.

Sävykoski T, Harju T, Paldanius M, Kuitunen H, Bloigu A, Wahlström E, Rytilä P, Kinnula V, Saikku P, Leinonen M.

Respiration. 2004 Mar-Apr;71(2):120-5.

PMID:
15031565
36.

No effect of montelukast on asthma-like symptoms in elite ice hockey players.

Helenius I, Lumme A, Ounap J, Obase Y, Rytilä P, Sarna S, Alaranta A, Remes V, Haahtela T.

Allergy. 2004 Jan;59(1):39-44.

37.

Smoking and atopy as determinants of sputum eosinophilia and bronchial hyper-responsiveness in adults with normal lung function.

Petäys T, von Hertzen L, Metso T, Rytilä P, Jousilahti P, Helenius I, Vartiainen E, Haahtela T.

Respir Med. 2003 Aug;97(8):947-54.

38.

Airway inflammation, bronchial hyperresponsiveness and asthma in elite ice hockey players.

Lumme A, Haahtela T, Ounap J, Rytilä P, Obase Y, Helenius M, Remes V, Helenius I.

Eur Respir J. 2003 Jul;22(1):113-7.

39.

[New non-invasive assessments of inflammation process in asthma].

Rytilä P, Malmberg P.

Duodecim. 2003;119(11):1039-47. Review. Finnish. No abstract available.

PMID:
12856433
40.

Sputum induction in children.

Gibson PG, Grootendor DC, Henry RL, Pin I, Rytila PH, Wark P, Wilson N, Djukanović R.

Eur Respir J Suppl. 2002 Sep;37:44s-46s. Review. No abstract available.

41.

Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5-year prospective follow-up study of 42 highly trained swimmers.

Helenius I, Rytilä P, Sarna S, Lumme A, Helenius M, Remes V, Haahtela T.

J Allergy Clin Immunol. 2002 Jun;109(6):962-8.

PMID:
12063525
42.

Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients.

Tukiainen H, Rytilä P, Hämäläinen KM, Silvasti MS, Keski-Karhu J; Finnish Study Group.

Respir Med. 2002 Apr;96(4):221-9.

43.

Eosinophilic airway inflammation as an underlying mechanism of undiagnosed prolonged cough in primary healthcare patients.

Rytilä P, Metso T, Petäys T, Sohlman A, Työlahti H, Kohonen-Jalonen P, Kiviniemi P, Haahtela T.

Respir Med. 2002 Jan;96(1):52-8.

44.
45.

Airway inflammation in patients with symptoms suggesting asthma but with normal lung function.

Rytilä P, Metso T, Heikkinen K, Saarelainen P, Helenius IJ, Haahtela T.

Eur Respir J. 2000 Nov;16(5):824-30.

46.

Safety of sputum induction in chronic obstructive pulmonary disease.

Rytilä PH, Lindqvist AE, Laitinen LA.

Eur Respir J. 2000 Jun;15(6):1116-9.

47.

The cellular composition of induced sputum in chronic obstructive pulmonary disease.

Peleman RA, Rytilä PH, Kips JC, Joos GF, Pauwels RA.

Eur Respir J. 1999 Apr;13(4):839-43.

48.

Respiratory symptoms, bronchial responsiveness, and cellular characteristics of induced sputum in elite swimmers.

Helenius IJ, Rytilä P, Metso T, Haahtela T, Venge P, Tikkanen HO.

Allergy. 1998 Apr;53(4):346-52.

49.
50.

[A rapid dosimetric method for histamine challenge in asthma diagnosis].

Sovijärvi A, Malmberg P, Reinikainen K, Rytilä P, Poppius H.

Duodecim. 1993;109(11):991-8. Finnish. No abstract available.

PMID:
8062672

Supplemental Content

Loading ...
Support Center